Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 pos KEAP1 mut |
Therapy | Pembrolizumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 pos KEAP1 mut | lung non-small cell carcinoma | not predictive | Pembrolizumab | Clinical Study | Actionable | In a retrospective analysis of a Phase III trial (KEYNOTE-042), Keytruda (pembrolizumab) treatment resulted in a similar improved overall survival compared to chemotherapy in patients with CD274 (PD-L1)-positive non-small cell lung cancer with either a KEAP1 mutation (HR=0.75) or wild-type KEAP1 (HR=0.78) (PMID: 36709038; NCT02220894). | 36709038 |
PubMed Id | Reference Title | Details |
---|---|---|
(36709038) | Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. | Full reference... |